No Data
No Data
Fosun Pharma Boosts Equity in Key Funds
Express News | Shanghai Fosun Pharma - Ningbo Fuying Will Acquire Equity Interests of RMB200.00 of Fund
Shanghai Fosun Pharma's New Strategic Agreements With Fosun International
FOSUN PHARMA (600196.SH): The controlling subsidiary intends to increase its shareholding in the Fund.
On December 11, Gelonghui reported that FOSUN PHARMA (600196.SH) announced that its holding subsidiary Ningbo Fuying, as an LP of the Nanjing Fund, Dalian Star Future Fund, and Suzhou Angel Fund, signed transfer agreements with FOSUN High Technology regarding the Shareholding of several property interests in these funds. The total consideration for this Shareholding is 140.42 million yuan, which includes: (1) a proposed investment of 90.92 million yuan to acquire another LP share of the Nanjing Fund, for which FOSUN High Technology has already contributed 200 million yuan, accounting for about 25.09% of the total contributed amount of this fund (of which 11 million yuan has been paid in).
On December 9, Fosun Pharma (02196.HK) spent 4.36 million Hong Kong dollars to repurchase 306,000 shares.
Gelonghui, December 9th丨Fosun Pharma (02196.HK) announced that on December 9, 2024, it spent 4.36 million Hong Kong dollars to repurchase 0.306 million shares at a price of 14.1-14.5 Hong Kong dollars per share.
Bearish landing? Hong Kong stocks in the pharmaceutical sector collectively strengthen with wuxi apptec rising over 8%.
① How much impact did the biological safety legislation have on domestic pharmaceutical stocks previously? ② How do industry insiders view the subsequent development of the biological legislation?
No Data